Suven Life Sciences Ltd

Suven Life Scie. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Suven Life Sciences Ltd

₹ 279 4.56%
29 May - close price
suven.com BSE: 530239 NSE: SUVEN
About

Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.[1]

Key Points

Primary Focus
The company has been working towards developing new molecules/ compounds in the complex CNS (central nervous system) space. [1]
Most of its lead molecules address the niche areas of cognitive impairments such as amnesia, dementia, narcolepsy, Alzheimer's, delirium, etc. [2]
CNS is the 2nd largest therapeutic category in the pharmaceutical industry and is also one of the fastest growing segments. [3]

Website BSE NSE
  • Market Cap ₹ 7,374 Cr.
  • Current Price ₹ 279
  • High / Low ₹ 303 / 124
  • Stock P/E
  • Book Value ₹ 22.4
  • Dividend Yield 0.00 %
  • ROCE -76.9 %
  • ROE -78.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Promoter holding has increased by 2.79% over last quarter.

Cons

  • Stock is trading at 12.5 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -12.0% over past five years.
  • Company has a low return on equity of -64.8% over last 3 years.
  • Debtor days have increased from 63.7 to 77.5 days.
  • Working capital days have increased from 2,939 days to 9,156 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
3 4 3 2 2 1 3 2 1 2 1 3 2
34 32 27 49 33 32 55 41 45 53 81 106 52
Operating Profit -32 -28 -24 -46 -30 -31 -52 -39 -44 -51 -80 -103 -51
OPM % -1,208% -737% -768% -1,885% -1,267% -3,024% -2,032% -2,435% -2,981% -2,714% -8,671% -3,678% -3,331%
6 6 13 6 4 4 4 2 1 1 4 3 7
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 2 2 2 2 2 1 1 2 1 1 1 1 2
Profit before tax -28 -24 -13 -42 -28 -28 -50 -39 -44 -52 -77 -102 -46
Tax % 0% 0% 0% 0% -4% 0% 0% 0% 0% 0% 0% 0% 0%
-28 -24 -13 -42 -27 -28 -50 -39 -44 -52 -77 -102 -46
EPS in Rs -1.27 -1.10 -0.58 -1.91 -1.22 -1.29 -2.28 -1.79 -2.01 -2.36 -3.40 -4.48 -1.73
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
521 499 543 625 286 13 13 12 14 12 7 7
361 398 414 427 300 128 93 134 139 140 172 292
Operating Profit 159 102 129 198 -14 -116 -80 -122 -126 -128 -166 -284
OPM % 31% 20% 24% 32% -5% -917% -593% -1,032% -929% -1,094% -2,487% -4,001%
9 19 21 23 27 14 8 5 14 29 11 14
Interest 5 6 6 5 2 1 1 1 0 0 0 0
Depreciation 12 18 21 21 11 4 4 4 7 6 6 6
Profit before tax 152 98 123 196 0 -106 -77 -122 -118 -106 -161 -276
Tax % 28% 26% 29% 37% 15,038% -11% -7% 0% 0% -1% 0% 0%
109 72 87 124 -24 -94 -72 -122 -118 -105 -161 -276
EPS in Rs 5.70 3.76 4.57 6.48 -1.25 -4.94 -3.78 -5.59 -5.42 -4.82 -7.37 -10.48
Dividend Payout % 7% 35% 15% 15% -80% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -35%
5 Years: -12%
3 Years: -19%
TTM: 7%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -67%
Stock Price CAGR
10 Years: 35%
5 Years: 26%
3 Years: 71%
1 Year: 21%
Return on Equity
10 Years: -24%
5 Years: -68%
3 Years: -65%
Last Year: -79%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 13 13 13 13 13 13 13 15 22 22 22 26
Reserves 547 583 654 755 226 131 95 82 354 248 88 565
109 83 71 34 3 6 5 3 2 1 0 17
105 74 78 118 62 33 16 9 12 14 25 16
Total Liabilities 773 751 816 919 303 182 128 108 389 285 135 624
172 305 306 308 22 25 21 38 37 28 60 73
CWIP 107 7 10 25 0 0 5 4 0 0 0 4
Investments 0 0 301 279 223 0 0 45 46 76 22 181
494 439 199 308 58 157 103 22 305 181 53 367
Total Assets 773 751 816 919 303 182 128 108 389 285 135 624

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
143 68 109 70 -53 -135 -96 -128 -116 -115 -154 -302
-110 -39 -311 -1 30 146 56 -22 -248 94 155 -462
179 -68 -30 -52 5 3 35 146 396 -1 -1 757
Net Cash Flow 212 -39 -232 17 -18 14 -5 -4 32 -22 0 -7
Free Cash Flow 25 10 79 28 -92 -137 -102 -147 -119 -113 -191 -307
CFO/OP 113% 93% 111% 57% 262% 114% 119% 104% 91% 95% 93% 106%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 28 39 31 36 3 66 48 40 22 40 73 78
Inventory Days 165 183 222 329 0
Days Payable 89 78 91 134
Cash Conversion Cycle 105 144 162 231 3 66 48 40 22 40 73 78
Working Capital Days 49 55 42 82 23 704 1,084 234 265 101 -440 9,156
ROCE % 13% 15% 24% -4% -54% -58% -118% -53% -36% -87% -77%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Clinical Stage Molecules (NCE Pipeline)
Number ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Total Permanent Employees
Number ・Standalone data
Global Product Patents Granted (Cumulative)
Number ・Standalone data
Number of R&D Scientists
Number ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
69.56% 69.56% 69.56% 69.56% 70.26% 70.26% 70.26% 70.26% 70.26% 67.36% 67.36% 70.15%
0.48% 0.50% 0.54% 0.46% 0.45% 0.33% 0.34% 0.25% 0.58% 1.17% 1.07% 0.91%
0.08% 0.01% 0.01% 1.05% 1.05% 1.05% 1.05% 0.01% 0.03% 3.39% 3.39% 4.62%
29.88% 29.92% 29.88% 28.91% 28.21% 28.34% 28.35% 29.47% 29.12% 28.07% 28.18% 24.32%
No. of Shareholders 76,29180,95374,00368,95966,11663,97563,53764,60366,15964,92164,38163,915

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls